Ticker LaunchIPO · RAIN
Rain Oncology Inc.
Formerly Rain Therapeutics Inc.
Rain Oncology Inc. (RAIN) priced its initial public offering on Apr 23, 2021 at $17.00 per share, within its $16.00–$18.00 range, raising $125M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $441.5M. Gibson Dunn advised the company and Latham & Watkins advised the underwriters.
Rain Oncology Inc. is a clinical-stage precision oncology company developing therapies for tumors with specific genetic drivers, selecting patients by genetics rather than tumor type. Its lead candidate, RAIN-32 (milademetan), is an oral MDM2 inhibitor.
- Status
- IPO
- Ticker
- RAIN
- Exchange
- Nasdaq Global Select
- Priced
- Apr 23, 2021
- IPO price
- $17.00
- Price range
- $16.00–$18.00
- Raised
- $125M
- Market cap at IPO price
- $441.5M
- First filed
- Apr 2, 2021
- Company counsel
- Gibson Dunn
- Underwriters' counsel
- Latham & Watkins
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 2, 2021
- Latest amendment Apr 19, 2021
- Final prospectus (424B4) Apr 23, 2021
- All filings on EDGAR CIK 1724979
Other Biotech & pharma IPOs in 2021
- Barinthus Biotherapeutics plc.VACC · Apr 30, 2021
- Werewolf Therapeutics, Inc.HOWL · Apr 30, 2021 · $120M
- Zymergen Inc.ZY · Apr 23, 2021
- IPI Legacy Liquidation CoIMPL · Apr 23, 2021 · $80M
- Biomea Fusion, Inc.BMEA · Apr 19, 2021 · $153M
- Recursion Pharmaceuticals, Inc.RXRX · Apr 16, 2021 · $436.4M